Opinion
Video
Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights
The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.
EP: 1.Clinical Scenario I: 68-yr Old Man with Early Relapse MM
EP: 2.Clinical Insights on Next Treatment Approach Steps
EP: 3.Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens
EP: 4.Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM
EP: 5.Overview of CAR T-cell Therapy Options in R/R MM
EP: 6.Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways
EP: 7.Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy
EP: 8.Clinical Insights on the Patient Presentation & Treatment Course
Now Viewing
EP: 9.Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights
EP: 10.Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM
Video content above is prompted by the following:
- What is your treatment sequencing approach for those who already received T-cell engaging therapies?
- What are some treatment options for those who have already received T-cell directed therapies in the R/R MM setting?
Related Videos
Related Content
